Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Maintenance Therapy for DLBCL

January 13th 2017

Treating High-Grade Lymphoma

January 13th 2017

Risk-Based Therapy for DLBCL

January 13th 2017

CAR-T Cell Therapies in CLL

January 13th 2017

Ibrutinib for CLL with Deletion 17p

January 13th 2017

Managing Ibrutinib Toxicity in CLL

January 13th 2017

Sequencing Therapies for Relapsed/Refractory CLL

January 13th 2017

The Role of Maintenance Therapy in CLL

January 13th 2017

CLL Risk Stratification and Treatment Approach

January 13th 2017

Chronic Lymphocytic Leukemia; Initiating Therapy

January 13th 2017

Emerging Therapies for Follicular Lymphoma

January 13th 2017

R2-CHOP for Relapsed Follicular Lymphoma

January 13th 2017

Sequencing Therapies for Follicular Lymphoma

January 13th 2017

Follicular Lymphoma: Consolidation and Maintenance

January 13th 2017

Follicular Lymphoma; Triggers to Initiate Therapy

January 13th 2017

Expert Highlights Efficacy of KTE-C19 CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 6th 2017

KTE-C19, an investigational CAR T-cell therapy, recently demonstrated positive results for patients with chemorefractory aggressive non-Hodgkin lymphoma.

R-CHOP Remains Frontline Standard in DLBCL, Says Expert

January 5th 2017

The regimen of rituximab plus CHOP chemotherapy has been the standard of care for patients with previously untreated diffuse large B-cell lymphoma for several years, and it appears it will remain that way for now, despite recent research to find novel alternatives.

Expert Explains WHO Classification Refinements in Hematologic Malignancies

December 30th 2016

Changes are underway in the field of hematologic malignancies, as the World Health Organization is publishing a revised classification of tumors of hematopoietic and lymphoid tissues—slated to be released in early 2017.

Dr. Neelapu on Interim Results of the Phase II ZUMA-1 Study in DLBCL

December 29th 2016

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses interim results of the phase II ZUMA-1 study in patients with diffuse large B-cell lymphoma.

FDA Grants JCAR017 Breakthrough Designation for Non-Hodgkin Lymphoma

December 21st 2016

JCAR017 has received an FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory, aggressive large B-cell non-Hodgkin lymphoma.